BIODESIX INC

BDSX

Explore Our Financial Data > Companies > BIODESIX INC
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
BDSX
CIK0001439725
SIC8071
SectorServices
Industry CategoryHealthcare
Industry GroupServices – Health

Contact

Address919 WEST DILLON ROAD, LOUISVILLE, CO, 80027
Website biodesix.com
Phone303-417-0500
CEOScott Hutton
Employees220

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$102.94 million
Pre-Tax Income$-27.76 million
Net Income$-27.76 million
Net Income to Common$-27.76 million
EPS$-2.70
View All
Balance Sheet
Cash$30.00 million
Assets$95.33 million
Liabilities$86.18 million
Common Equity$9.14 million
Liabilities & Equity$95.33 million
View All
Cash Flow Statement
Net Income$-27.76 million
Cash From Operating Activities$-19.83 million
Cash From Investing Activities$-569,000.00
Cash From Financing Activities$29.67 million
Change in Cash$9.27 million
View All
Calculations
NOPAT$-14.42 million
EBITDA$-12.77 million
Price to EarningsN/A
Price to Book$24.44
ROE-540.01%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Biodesix to Report Third Quarter 2026 Financial Results on November 5, 2026

LOUISVILLE, Colo., Oct. 22, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the third quarter ended September 30, 2026 after the close of trading on Thursday, November 5. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this

Article Link

American College of Chest Physicians Publishes New Framework for Lung Nodule Programs Recommending Biomarkers for Risk Stratification

New CHEST framework developed by a renowned multidisciplinary panel with expertise in building and managing lung nodule programs across diverse clinical practicesLOUISVILLE, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc (NASDAQ: BDSX), a leader in diagnostic solutions, today announced that the American College of Chest Physicians (CHEST) has published a new framework for clinical practice, “Building a Lung Nodule Program: From Detection to Diagnosis.” This groundbreaking framework descr

Article Link

Biodesix Adds Digital Diagnostics to Lung Pipeline, Creating New Growth Platform Combining Blood and Imaging Biomarkers

Partnership with Vanderbilt University and Vanderbilt Health accelerates development of the first radiomics-based test for lung nodule risk assessmentLOUISVILLE, Colo., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced the addition of Digital Diagnostics to its Lung Diagnostics strategy, establishing the foundation for a multimodal diagnostic platform that combines blood-based biomarkers, imaging biomarkers, and artificial i

Article Link

Biodesix (BDSX) Stock Sees Fair Value Lift As Analysts Back MRD Growth

Biodesix now carries a higher fair value estimate, with the assessed price target moving from US$34 to US$39, which is about a 15% change in the latest model. Recent analyst commentary links this shift to interest in the company’s Molecular Residual Disease offerings and broader diagnostics exposure, as well as recognition of execution and reimbursement questions that still exist. In the sections that follow, you will see how these moving pieces shape the evolving Biodesix narrative and what...

Article Link

Biodesix to Present New Real-World Evidence Supporting Integration of Nodify Lung® Testing into Routine Lung Nodule Care at CHEST 2026

New sponsored and independent research evaluates clinical utility, patient follow-up, and diagnostic test sequencingLOUISVILLE, Colo., Oct. 13, 2026 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX), a leading diagnostics solutions company, today announced multiple presentations at CHEST 2026 highlighting how Nodify Lung testing is being incorporated into real-world lung nodule management. The presentations build upon the strong evidence base with new use cases and clinical comparisons, illustra

Article Link